Anneke Westermann

5PUBLICATIONS
59CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 07, 2024
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.

Dione van Dijk, Lisa Vermij, Alicia León-Castillo

|Jan 06, 2024
PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.

Anneke Westermann, Petronella Ottevanger, An Reyners

|Aug 31, 2023
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.

Ignace Vergote, Els Van Nieuwenhuysen, Roisin E O'Cearbhaill

|Aug 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.

Rachel N Grisham, Ignace Vergote, Susana Banerjee

|Feb 10, 2022
A randomized phase-II study of reirradiation and hyperthermia versus reirradiation and hyperthermia plus chemotherapy for locally recurrent breast cancer in previously irradiated area.

Daphne Schouten, Rob van Os, Anneke M Westermann

Pageof 1

Frequent Collaborators

2 joint publications

Ignace Vergote

2 joint publications

Susana Banerjee

2 joint publications

Bradley J Monk

2 joint publications

David Cibula